FDA warned Enlifta that it sells unapproved new drugs for depression and anxiety through its website and Amazon.
What happened
FDA reviewed Enlifta's websites in December 2020 and February 2021 and its linked Amazon product pages. FDA found claims and testimonials saying “Enlifta Mood Elevator” and “Enlifta Anxiety” treat depression and anxiety. FDA says these claims make the supplements drugs, and that they are unapproved new drugs and misbranded because they lack adequate directions for safe use by laypeople.
What FDA found
The products are drugs because the website and Amazon claims say they are intended to treat depression and anxiety.
section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]The products are unapproved new drugs because they are not generally recognized as safe and effective for those uses and have no FDA approval.
sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. §§ 321(p), 331(d), 355(a)]The products are misbranded because they lack adequate directions for use for conditions that a layperson cannot safely diagnose or treat without a licensed practitioner.
section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 CFR § 201.5Introducing or delivering these misbranded drugs into interstate commerce violates the Act.
section 301(a) of the Act [21 U.S.C. § 331(a)]
What FDA wants
FDA asks Enlifta to take prompt action to correct the violations and to notify FDA in writing within 15 working days of the steps taken, with supporting documents, or explain why the products are not violations.
Who should pay attention
- online supplement sellers making disease-treatment claims
- retailers and marketplaces hosting supplement listings
- consumers using supplements for depression or anxiety
This is a summary. Read the original letter on fda.gov.